Eosinophilic Enteritis
- Home
- Solutions
- By Diseases
- Intestinal Diseases
- Eosinophilic Enteritis
Eosinophilic enteritis is a rare idiopathic eosinophilic infiltration of any segment of the intestinal wall that disrupts the gastrointestinal tract. The manifestations depend upon the segment involved and the layer of intestine infiltrated. As a service provider of research, Protheragen offers full-blown services for the therapeutic development of eosinophilic enteritis from drug discovery to preclinical research phases using the latest technologies and expertise.
Eosinophilic enteritis, otherwise known as eosinophilic gastroenteritis, is a complex disorder of the digestive system involving eosinophils. It is primarily defined by an intense level of eosinophile infiltration in histopathological investigations of intestinal tissues. Its prevalence rate is 5/100,000 people and is quite common in children 5 years old or younger. Depending on which layer of the abdominal wall is affected, it can present itself as pain in the abdomen, diarrhea, nausea, vomiting, bloating, intestinal blockage, or fluid accumulation in the abdomen.
Fig.1 Biopsy of an individual with eosinophilic enteritis. (Rienzo-Madero, B., et al., 2023)Eosinophils are formed in the bone marrow, differentiate, and proliferate under the influence of cytokines such as GM-CSF, IL-3, and IL-5, eosinophils are released into the bloodstream where they travel to specific organs. Many signals can activate eosinophils, including tissue injury, parasitic infection, bacterial infection, and allergies. In the gastrointestinal tract, activation of eosinophils will cause tissue damage and is responsible for the symptoms seen in individuals with eosinophilic enteritis. Besides the delayed Th2 adaptive response, a direct IgE-dependent response can also contribute to the pathophysiology of eosinophilic enteritis.
| Drug Names | Mechanism of Action | Targets | Research Phase |
| Budesonide | It attaches to and activates glucocorticoid receptors (GR) in the cytoplasm of the effector cells. | GR | Approved |
| Montelukast | A selective leukotriene receptor antagonist with a high binding affinity to the cysteinyl leukotriene receptor. | CysLT1 | Approved |
| RPC4046 | It hinders IL13 from conjugating with receptor subunits IL13RA1 and IL13RA2. | IL13 | Phase III |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
As a cutting-edge research services provider, we specialize in offering end-to-end solutions for eosinophilic enteritis therapeutic development, such as diagnostic, therapeutic, and disease model development services. With a dedicated focus on innovation and scientific excellence, we are committed to advancing the understanding and therapy of this complex gastrointestinal disorder.
Animal models play a crucial role in understanding the pathophysiology of the disease and in evaluating possible therapeutic approaches. A range of animal models that simulate the features of eosinophilic enteritis for preclinical investigations are offered by our company.
Chemicals like dextran sulfate sodium (DSS) or ovalbumin (OVA) can be administered to cause inflammation of the intestines and infiltration of eosinophils which creates the eosinophilic enteritis model that the disease's mechanisms can be studied.
At the forefront of scientific innovation, Protheragen integrates cutting-edge technologies and methodologies to drive advancements in eosinophilic enteritis research. Our services span from pharmacokinetic studies to drug safety evaluations in eosinophilic enteritis drug research and development. If you are interested in our services, please do not hesitate to contact us.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.